This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal

Cormorant Asset Management sold 775,000 Arcellx shares in Q4, reducing its quarter-end position value by $63.63 million to zero as it fully exited the holding. The disclosure signals a complete position liquidation by the fund and may exert modest near-term pressure on Arcellx shares, but is largely a routine portfolio-level trade.

Analysis

Cormorant Asset Management sold 775,000 Arcellx shares in Q4, reducing its quarter-end position value by $63.63 million to zero as it fully exited the holding. The disclosure signals a complete position liquidation by the fund and may exert modest near-term pressure on Arcellx shares, but is largely a routine portfolio-level trade.